Literature DB >> 22332980

Interactions between antiepileptics and second-generation antipsychotics.

Jose de Leon1, Vincenza Santoro, Concetta D'Arrigo, Edoardo Spina.   

Abstract

INTRODUCTION: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED-SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder. AREAS COVERED: This article provides a comprehensive review of the interactions between antiepileptics and second-generation antipsychotics. The authors cover pharmacokinetic AED-SGAP DI studies, the newest drug pharmacokinetics in addition to the limited pharmacodynamic DI studies. EXPERT OPINION: Dosing correction factors and measuring SGAP levels can help to compensate for the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. Further studies are needed to establish the clinical relevance of combining: i) AED strong inducers with amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and olanzapine; iii) high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate (≥ 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in bipolar disorder, ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and swallowing disturbances. A few AED-SGAP combinations may increase risk for osteoporosis or nausea. Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leukopenia and heat stroke. The authors believe that collaboration is needed from drug agencies and pharmaceutical companies, the clinicians using these combinations, researchers with expertise in meta-analyses, grant agencies, pharmacoepidemiologists and DI pharmacologists for future progression in this field.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22332980     DOI: 10.1517/17425255.2012.660918

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  12 in total

Review 1.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

2.  Can valproic acid be an inducer of clozapine metabolism?

Authors:  F J Diaz; C B Eap; N Ansermot; S Crettol; E Spina; J de Leon
Journal:  Pharmacopsychiatry       Date:  2014-04-24       Impact factor: 5.788

3.  Interaction between clozapine and oxcarbazepine: a case report.

Authors:  Hazel Yousra; Lebain Pierrick; Lecardeur Laurent; Debruyne Danièle
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-15

Review 4.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

5.  Response to clozapine in a clinically identifiable subtype of schizophrenia.

Authors:  Nancy J Butcher; Wai Lun Alan Fung; Laura Fitzpatrick; Alina Guna; Danielle M Andrade; Anthony E Lang; Eva W C Chow; Anne S Bassett
Journal:  Br J Psychiatry       Date:  2015-03-05       Impact factor: 9.319

Review 6.  Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder.

Authors:  Jose de Leon; Edoardo Spina
Journal:  Curr Psychiatry Rep       Date:  2018-03-12       Impact factor: 5.285

7.  Sudden-onset dystonia in a patient taking asenapine: interaction between ciprofloxacin and asenapine metabolism.

Authors:  Kathryn K Ridout; Samuel J Ridout; Loreen F Pirnie; Sharath P Puttichanda
Journal:  Am J Psychiatry       Date:  2015-11-01       Impact factor: 18.112

Review 8.  Clinical applications of CYP genotyping in psychiatry.

Authors:  Edoardo Spina; Jose de Leon
Journal:  J Neural Transm (Vienna)       Date:  2014-09-09       Impact factor: 3.575

9.  Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms.

Authors:  Isaac Schweitzer; Jerome Sarris; Virginia Tuckwell; Kay Maguire; Deidre Smith; Chee Ng
Journal:  Int J Bipolar Disord       Date:  2013-04-17

10.  Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular Antipsychotics.

Authors:  Nasratullah Wahidi; Katie M Johnson; Allen Brenzel; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2016-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.